PT44 Cost-Effectiveness of Olaparib Vs. Rucaparib for Patients with Metastatic Castration-Resistant Prostate Cancer – the Canadian Perspective
Dec 1, 2023, 00:00 AM
10.1016/j.jval.2023.09.1034
https://www.valueinhealthjournal.com/article/S1098-3015(23)04164-5/fulltext
Section Title :
Section Order :
10529
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)04164-5&doi=10.1016/j.jval.2023.09.1034